Related Resources for this page:
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- Clinical Trials
- Cancer Biomarkers
- Future Directions
- Antibody-Drug Conjugates
- A brief history of ADCs
- Current research in ADCs
- Cytotoxic agent
- Emerging therapeutic options
- Emerging therapeutic options
- HER Signaling
- How are ADCs designed to work?
- Glossary
- Monoclonal antibody
- Research ADCs
- Slide decks and videos
- Stable linker
- Summary
- Targeting cancers with ADCs
- Trastuzumab Emtansine (T-DM1)
- What are ADCs?
- Antibody-Drug conjugates
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Traditional Monoclonal Antibodies
- Anti-EGFL7
- Glossary
- Emerging therapeutic options
- Emerging therapeutic options
- Gastric Cancer
- HER Signaling
- HER1/EGFR as a therapeutic target
- HER2:HER3 dimer
- HER2 as a therapeutic target
- HER3 as a therapeutic target
- Melanoma
- Summary
- Angiogenic Signaling
- Inhibition of HER2 dimerization
- Therapeutic potential of HER pathways
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- Antibody-Drug Conjugates
Ovarian Cancer
Disease Information
Genentech BioOncology is dedicated to advancing the science of ovarian cancer therapy through comprehensive research and education. Ovarian cancer is a malignancy that initiates in the ovaries.1 Based on the source of origin, ovarian tumors are classified into 3 different categories.2
Epithelial ovarian tumors
Most ovarian tumors are of epithelial origin and arise from cells that cover the outer surface of the ovary.2 Ovarian tumors may be benign or malignant in clinical behavior.2 Benign epithelial tumors do not spread to distant organs and therefore do not usually cause serious illness.2 A number of benign epithelial tumors have been identified that include serous adenomas, mucinous adenomas, and Brenner tumors.2
Malignant epithelial cancers, referred to as carcinomas, constitute ≈85% to ≈90% of epithelial ovarian cancers.2
- Based on their unique morphologic features, malignant epithelial ovarian carcinoma tumors may be classified into serous, mucinous, endometrioid, and clear cell subtypes. If the tumor cells do not exhibit any of the 4 morphologic types, they are classified as undifferentiated types; these tumors typically grow and spread more quickly than their differentiated counterparts2
- Malignant ovarian epithelial tumors may also include 2 rare subtypes, namely, primary peritoneal carcinoma and fallopian tube cancers.2 The latter tumor subtype has a marginally better prognosis than other ovarian cancers2
- Ovarian cancers may sometimes include slow-growing tumors of low malignant potential, referred to as borderline epithelial ovarian cancers.2 These tumors are less life-threatening than most ovarian cancers and tend to affect women at a younger age2
Ovarian germ cell tumors
Ovarian germ cell tumors typically originate from germ cells that produce the eggs and account for less than 2% of all ovarian cancers.2 Most ovarian germ cell tumors are considered benign in nature and are associated with a good prognosis; studies reveal that 90% of patients afflicted with ovarian germ cell tumors survive at least 5 years after initial diagnosis.2 Depending upon the morphologic features, ovarian germ cell tumors may be grouped into 5 major categories, namely teratoma, dysgerminoma, endodermal sinus tumor, and choriocarcinoma.2
Ovarian stromal cell tumors
About 1% of ovarian cancers are designated as ovarian stromal cell tumors.2 The majority of the stromal tumors are found in women older than 50, with only ≈5% of stromal tumors reported in young girls.2 These tumors typically originate from stromal tissue and produce the female hormones estrogen and progesterone.2 Based on morphologic features, malignant stromal tumors may be divided into granulosa cell tumors (the most common type), granulosa-theca tumors, and Sertoli-Leydig cell tumors.2
Ovarian Cancer Demographic Statistics
- Ovarian cancer ranks second among gynecologic cancers, accounting for an estimated 21,880 new cases in 2010 in the United States3
- More deaths result from ovarian cancer than any other malignancy affecting the female reproductive system, accounting for an estimated 13,850 deaths in 2010 in the United States2
Ovarian Cancer Epidemiology
- New studies indicate that mutations in BRCA1 and BRCA2 genes may increase ovarian cancer risk2
- Other risk factors associated with ovarian cancer include family history of breast and ovarian cancers, estrogen and hormonal therapies, age, obesity, and the use of certain fertility drugs2
References:
- 1.
- US Department of Health and Human Services. National Cancer Institute. What you need to know about™ ovarian cancer. www.cancer.gov/cancertopics/wyntk/ovary/wyntk_ovarian.pdf. Accessed April 14, 2011.
- 2.
- American Cancer Society. Ovarian cancer. www.cancer.org/acs/groups/cid/documents/webcontent/003130-pdf.pdf. Accessed April 14, 2011.
- 3.
- American Cancer Society. Cancer Facts & Figures 2010. www.cancer.org/acs/groups/content/
@epidemiologysurveilance/documents/document/acspc-026238.pdf. Accessed April 14, 2011.